BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29052866)

  • 1. RUNX-mediated growth arrest and senescence are attenuated by diverse mechanisms in cells expressing RUNX1 fusion oncoproteins.
    Anderson G; Mackay N; Gilroy K; Hay J; Borland G; McDonald A; Bell M; Hassanudin SA; Cameron E; Neil JC; Kilbey A
    J Cell Biochem; 2018 Mar; 119(3):2750-2762. PubMed ID: 29052866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RUNX1 and its fusion oncoprotein derivative, RUNX1-ETO, induce senescence-like growth arrest independently of replicative stress.
    Wolyniec K; Wotton S; Kilbey A; Jenkins A; Terry A; Peters G; Stocking C; Cameron E; Neil JC
    Oncogene; 2009 Jul; 28(27):2502-12. PubMed ID: 19448675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis.
    Yan M; Ahn EY; Hiebert SW; Zhang DE
    Blood; 2009 Jan; 113(4):883-6. PubMed ID: 19036704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular targeting of aberrant transcription factors in leukemia: strategies for RUNX1/ETO.
    Wichmann C; Grez M; Lausen J
    Curr Drug Targets; 2010 Sep; 11(9):1181-91. PubMed ID: 20583973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
    Wichmann C; Chen L; Heinrich M; Baus D; Pfitzner E; Zörnig M; Ottmann OG; Grez M
    Cancer Res; 2007 Mar; 67(5):2280-9. PubMed ID: 17332359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ZBTB7A prevents RUNX1-RUNX1T1-dependent clonal expansion of human hematopoietic stem and progenitor cells.
    Redondo Monte E; Wilding A; Leubolt G; Kerbs P; Bagnoli JW; Hartmann L; Hiddemann W; Chen-Wichmann L; Krebs S; Blum H; Cusan M; Vick B; Jeremias I; Enard W; Theurich S; Wichmann C; Greif PA
    Oncogene; 2020 Apr; 39(15):3195-3205. PubMed ID: 32115572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elucidation of Novel Therapeutic Targets for Acute Myeloid Leukemias with
    Yun JW; Bae YK; Cho SY; Koo H; Kim HJ; Nam DH; Kim SH; Chun S; Joo KM; Park WY
    Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30959925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RUNX1-ETO induces a type I interferon response which negatively effects t(8;21)-induced increased self-renewal and leukemia development.
    DeKelver RC; Lewin B; Weng S; Yan M; Biggs J; Zhang DE
    Leuk Lymphoma; 2014 Apr; 55(4):884-91. PubMed ID: 23772668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compatibility of RUNX1/ETO fusion protein modules driving CD34+ human progenitor cell expansion.
    Chen-Wichmann L; Shvartsman M; Preiss C; Hockings C; Windisch R; Redondo Monte E; Leubolt G; Spiekermann K; Lausen J; Brendel C; Grez M; Greif PA; Wichmann C
    Oncogene; 2019 Jan; 38(2):261-272. PubMed ID: 30093631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cooperation between RUNX1-ETO9a and novel transcriptional partner KLF6 in upregulation of Alox5 in acute myeloid leukemia.
    DeKelver RC; Lewin B; Lam K; Komeno Y; Yan M; Rundle C; Lo MC; Zhang DE
    PLoS Genet; 2013; 9(10):e1003765. PubMed ID: 24130502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of transcriptional repression by TEL/RUNX1 fusion protein.
    Lee YJ; Kim JH; Bae S; Rho SK; Choe SY
    Mol Cells; 2004 Apr; 17(2):217-22. PubMed ID: 15179033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GFI1 is required for
    Marneth AE; Botezatu L; Hönes JM; Israël JCL; Schütte J; Vassen L; Lams RF; Bergevoet SM; Groothuis L; Mandoli A; Martens JHA; Huls G; Jansen JH; Dührsen U; Berg T; Möröy T; Wichmann C; Lo MC; Zhang DE; van der Reijden BA; Khandanpour C
    Haematologica; 2018 Sep; 103(9):e395-e399. PubMed ID: 29674496
    [No Abstract]   [Full Text] [Related]  

  • 13. MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML.
    Vegi NM; Klappacher J; Oswald F; Mulaw MA; Mandoli A; Thiel VN; Bamezai S; Feder K; Martens JHA; Rawat VPS; Mandal T; Quintanilla-Martinez L; Spiekermann K; Hiddemann W; Döhner K; Döhner H; Stunnenberg HG; Feuring-Buske M; Buske C
    Cell Rep; 2016 Jul; 16(2):498-507. PubMed ID: 27346355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The t(8;21) fusion protein RUNX1-ETO downregulates PKM2 in acute myeloid leukemia cells.
    Yan JS; Li YD; Liu SH; Yin QQ; Liu XY; Xia L; Lu Y
    Leuk Lymphoma; 2017 Aug; 58(8):1985-1988. PubMed ID: 28092997
    [No Abstract]   [Full Text] [Related]  

  • 15. Cell-intrinsic depletion of Aml1-ETO-expressing pre-leukemic hematopoietic stem cells by K-Ras activating mutation.
    Di Genua C; Norfo R; Rodriguez-Meira A; Wen WX; Drissen R; Booth CAG; Povinelli B; Repapi E; Gray N; Carrelha J; Kettyle LM; Jamieson L; Neo WH; Thongjuea S; Nerlov C; Mead AJ
    Haematologica; 2019 Nov; 104(11):2215-2224. PubMed ID: 30975913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
    Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
    Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation.
    Hartmann L; Dutta S; Opatz S; Vosberg S; Reiter K; Leubolt G; Metzeler KH; Herold T; Bamopoulos SA; Bräundl K; Zellmeier E; Ksienzyk B; Konstandin NP; Schneider S; Hopfner KP; Graf A; Krebs S; Blum H; Middeke JM; Stölzel F; Thiede C; Wolf S; Bohlander SK; Preiss C; Chen-Wichmann L; Wichmann C; Sauerland MC; Büchner T; Berdel WE; Wörmann BJ; Braess J; Hiddemann W; Spiekermann K; Greif PA
    Nat Commun; 2016 Jun; 7():11733. PubMed ID: 27252013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticle-mediated targeting of the fusion gene RUNX1/ETO in t(8;21)-positive acute myeloid leukaemia.
    Issa H; Swart LE; Rasouli M; Ashtiani M; Nakjang S; Jyotsana N; Schuschel K; Heuser M; Blair H; Heidenreich O
    Leukemia; 2023 Apr; 37(4):820-834. PubMed ID: 36823395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells.
    Goyama S; Schibler J; Cunningham L; Zhang Y; Rao Y; Nishimoto N; Nakagawa M; Olsson A; Wunderlich M; Link KA; Mizukawa B; Grimes HL; Kurokawa M; Liu PP; Huang G; Mulloy JC
    J Clin Invest; 2013 Sep; 123(9):3876-88. PubMed ID: 23979164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-expression of AML1-ETO and PML-RARa following treatment of de novo acute myeloid leukemia with AML1-ETO.
    Zhang S; Zhou W; Li Y; Yu S; Xue M; Qiao Y; Jian J; Liu B; Wang D
    Leuk Lymphoma; 2019 May; 60(5):1316-1319. PubMed ID: 30328750
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.